Skip to main

Impact case study database

The impact case study database allows you to browse and search for impact case studies submitted to the REF 2021. Use the search and filters below to find the impact case studies you are looking for.
Impact case study database FAQs
Download all impact case studies (spreadsheet)
Download all impact case studies (spreadsheet) (generating)
Download all impact case study tags (spreadsheet)
Download all impact case study tags (spreadsheet) (generating)
Back

A new first-in-class drug transforms treatment for heart failure, improves patient outcomes, and reduces hospitalisation

Download case study PDF
Submitting institution
University of Glasgow
Unit of assessment
1 - Clinical Medicine
Summary impact type
Health
Request cross-referral to
-
Is this case study continued from a case study submitted in 2014?
No
Underpinning research subjects
  • Cardiorespiratory Medicine And Haematology
  • Clinical Sciences
  • Public Health And Health Services

1. Summary of the impact

2. Underpinning research

3. References to the research

4. Details of the impact

5. Sources to corroborate the impact

Additional contextual information

Grant funding

Grant number Value of grant
PG/17/23/32850 £295,604
Countries
  • UK
  • USA
  • EU countries
  • Canada
  • Australia
  • New Zealand
  • Worldwide (encompassing 112 countries)
Formal partners
  • Novartis; NHS Greater Glasgow and Clyde
Funding programmes
  • Grant – ‘ Effect of sacubitril/valsartan compared to valsartan on left ventricular remodelling in patients with asymptomatic left ventricular systolic dysfunction after myocardial infarction.’ 2018 - 2021
  • Clinical Trial – ‘ A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction.’ 2018 - 2020
  • Contract Research – ‘Analysis of Data collected from the PARADIGM-HF Trial.’ 2019 - 2019
  • Contract Research – ‘‘Analysis of Data collected from the PARADIGM-HF Trial.’ 2014 - 2019
  • Clinical Trial – ‘Multicenter, randomized, doubleblind, parallel group, activecontrolled study to evaluate the efficacy/safety of LCZ696 compared to valsartan..’ 2015 - 2018
  • Clinical Trial – ‘Effects of sacubitril/valsartan compared to valsartan on left ventricular remodelling in asymptomatic LVSD after myocardial infarction: randomized, double-blinded active-comparator cardiac MR trial’ 2018 - 2020
Global research identifiers
  • grid.452924.c
  • grid.419481.1
  • grid.418424.f
  • grid.418607.c
Name of funders
  • British Heart Foundation
  • Novartis (CH)
  • Novartis (US)
  • Novartis (UK)
Researcher ORCIDs
  • 0000-0002-6317-3975
  • 0000-0003-4306-5317